GRI Bio shares surge 42.98% after hours on positive Phase 2a IPF trial results showing safety and biomarker improvements.

GRI Bio surged 42.98% in after-hours trading following the release of positive Phase 2a trial data for its lead candidate, GRI-0621, in idiopathic pulmonary fibrosis (IPF). The study demonstrated the drug’s safety over 12 weeks, with no severe adverse events, and showed improvements in biomarkers indicating fibrosis resolution and alveolar basement membrane repair. Notably, 39% of treated subjects experienced increased forced vital capacity (FVC) at 12 weeks, compared to 80% of placebo-treated subjects who saw declines. The favorable safety profile, combined with evidence of disease-modifying potential, positions GRI-0621 as a promising treatment for IPF, a condition with limited therapeutic options. These results, highlighted in multiple press releases and summaries, directly drove investor optimism, aligning with the sharp after-hours rally.